炭疽(Anthrax):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Anthrax - Pipeline Review, H2 2014
◆商品コード:GMDHC5791IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月30日
◆ページ数:158
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における炭疽(Anthrax)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・炭疽(Anthrax)の概要
・炭疽(Anthrax)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・炭疽(Anthrax)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・炭疽(Anthrax)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・炭疽(Anthrax)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Anthrax – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Anthrax – Pipeline Review, H2 2014’, provides an overview of the Anthrax’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anthrax, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anthrax and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anthrax
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Anthrax and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Anthrax products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Anthrax pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Anthrax
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Anthrax pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Anthrax Overview 8
Therapeutics Development 9
Pipeline Products for Anthrax – Overview 9
Pipeline Products for Anthrax – Comparative Analysis 10
Anthrax – Therapeutics under Development by Companies 11
Anthrax – Therapeutics under Investigation by Universities/Institutes 14
Anthrax – Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Anthrax – Products under Development by Companies 18
Anthrax – Products under Investigation by Universities/Institutes 21
Anthrax – Companies Involved in Therapeutics Development 22
Aradigm Corporation 22
Bavarian Nordic A/S 23
Bristol-Myers Squibb Company 24
Cellceutix Corporation 25
ContraFect Corporation 26
Dynavax Technologies Corporation 27
Elusys Therapeutics, Inc. 28
Emergent BioSolutions Inc. 29
Evolva SA 30
Green Cross Corporation 31
Grifols, S.A. 32
Hawaii Biotech, Inc. 33
iBio, Inc. 34
Immunovaccine, Inc. 35
Innovative Biologics, Inc. 36
Microbiotix, Inc. 37
NanoBio Corporation 38
Navigen Pharmaceuticals, Inc. 39
Oragenics, Inc. 40
PaxVax 41
Pfenex Inc. 42
Planet Biotechnology Inc. 43
Protein Potential, LLC 44
ProThera Biologics, LLC. 45
PsiOxus Therapeutics, Ltd. 46
Revivicor, Inc. 47
SelectX Pharmaceuticals, Inc. 48
Soligenix, Inc. 49
Summit Corporation plc 50
Syntiron LLC 51
Tetraphase Pharmaceuticals Inc. 52
The Medicines Company 53
Vaxin, Inc. 54
Anthrax – Therapeutics Assessment 55
Assessment by Monotherapy Products 55
Assessment by Combination Products 56
Assessment by Target 57
Assessment by Mechanism of Action 59
Assessment by Route of Administration 61
Assessment by Molecule Type 63
Drug Profiles 65
anthrax + plague vaccine – Drug Profile 65
anthrax vaccine – Drug Profile 66
anthrax vaccine – Drug Profile 68
anthrax vaccine – Drug Profile 69
anthrax vaccine – Drug Profile 70
anthrax vaccine – Drug Profile 71
anthrax vaccine – Drug Profile 72
anthrax vaccine – Drug Profile 73
anthrax vaccine – Drug Profile 74
anthrax vaccine – Drug Profile 76
anthrax vaccine next generation – Drug Profile 77
ARD-3100 – Drug Profile 78
AV-7909 – Drug Profile 80
CF-307 – Drug Profile 81
CF-308 – Drug Profile 82
ciprofloxacin hydrochloride – Drug Profile 83
DV-230 – Drug Profile 84
EV-021 – Drug Profile 85
GC-1109 – Drug Profile 86
GREANX – Drug Profile 87
Human Antibody Based Vaccines – Drug Profile 88
KKL-35 – Drug Profile 90
MDX-1303 – Drug Profile 91
Monoclonal Antibody for Respiratory Anthrax – Drug Profile 93
Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax – Drug Profile 94
MU-1140 – Drug Profile 95
MVA-BN Anthrax – Drug Profile 97
NP-015 – Drug Profile 98
obiltoxaximab – Drug Profile 99
oritavancin diphosphate – Drug Profile 101
PBI-220 – Drug Profile 104
PMX-30016 – Drug Profile 106
PreviThrax – Drug Profile 107
Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis – Drug Profile 109
Px-563L – Drug Profile 110
RiVax + VeloThrax – Drug Profile 111
Second Generation Px-563L – Drug Profile 112
SGX-204 – Drug Profile 113
Slit2N – Drug Profile 114
Small Molecule to Agonize TLR for Anthrax – Drug Profile 116
Small Molecule to Inhibit Anthrax Toxin for Anthrax – Drug Profile 117
Small Molecules for Bacterial Infections – Drug Profile 118
Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax – Drug Profile 119
Small Molecules to Inhibit Lethal Factor for Anthrax – Drug Profile 120
Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis – Drug Profile 122
Small Molecules to Inhibit MMP – Drug Profile 123
SMT-15000 – Drug Profile 124
TP-271 – Drug Profile 125
Anthrax – Recent Pipeline Updates 127
Anthrax – Dormant Projects 141
Anthrax – Discontinued Products 142
Anthrax – Product Development Milestones 143
Featured News & Press Releases 143
Appendix 153
Methodology 153
Coverage 153
Secondary Research 153
Primary Research 153
Expert Panel Validation 153
Contact Us 154
Disclaimer 154

[List of Tables]
Number of Products under Development for Anthrax, H2 2014 13
Number of Products under Development for Anthrax - Comparative Analysis, H2 2014 14
Number of Products under Development by Companies, H2 2014 16
Number of Products under Development by Companies, H2 2014 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H2 2014 18
Comparative Analysis by Late Stage Development, H2 2014 19
Comparative Analysis by Clinical Stage Development, H2 2014 20
Comparative Analysis by Early Stage Development, H2 2014 21
Products under Development by Companies, H2 2014 22
Products under Development by Companies, H2 2014 (Contd..1) 23
Products under Development by Companies, H2 2014 (Contd..2) 24
Products under Investigation by Universities/Institutes, H2 2014 25
Anthrax - Pipeline by Aradigm Corporation, H2 2014 26
Anthrax - Pipeline by Bavarian Nordic A/S, H2 2014 27
Anthrax - Pipeline by Bristol-Myers Squibb Company, H2 2014 28
Anthrax - Pipeline by Cellceutix Corporation, H2 2014 29
Anthrax - Pipeline by ContraFect Corporation, H2 2014 30
Anthrax - Pipeline by Dynavax Technologies Corporation, H2 2014 31
Anthrax - Pipeline by Elusys Therapeutics, Inc., H2 2014 32
Anthrax - Pipeline by Emergent BioSolutions Inc., H2 2014 33
Anthrax - Pipeline by Evolva SA, H2 2014 34
Anthrax - Pipeline by Green Cross Corporation, H2 2014 35
Anthrax - Pipeline by Grifols, S.A., H2 2014 36
Anthrax - Pipeline by Hawaii Biotech, Inc., H2 2014 37
Anthrax - Pipeline by iBio, Inc., H2 2014 38
Anthrax - Pipeline by Immunovaccine, Inc., H2 2014 39
Anthrax - Pipeline by Innovative Biologics, Inc., H2 2014 40
Anthrax - Pipeline by Microbiotix, Inc., H2 2014 41
Anthrax - Pipeline by NanoBio Corporation, H2 2014 42
Anthrax - Pipeline by Navigen Pharmaceuticals, Inc., H2 2014 43
Anthrax - Pipeline by Oragenics, Inc., H2 2014 44
Anthrax - Pipeline by PaxVax, H2 2014 45
Anthrax - Pipeline by Pfenex Inc., H2 2014 46
Anthrax - Pipeline by Planet Biotechnology Inc., H2 2014 47
Anthrax - Pipeline by Protein Potential, LLC, H2 2014 48
Anthrax - Pipeline by ProThera Biologics, LLC., H2 2014 49
Anthrax - Pipeline by PsiOxus Therapeutics, Ltd., H2 2014 50
Anthrax - Pipeline by Revivicor, Inc., H2 2014 51
Anthrax - Pipeline by SelectX Pharmaceuticals, Inc., H2 2014 52
Anthrax - Pipeline by Soligenix, Inc., H2 2014 53
Anthrax - Pipeline by Summit Corporation plc, H2 2014 54
Anthrax - Pipeline by Syntiron LLC, H2 2014 55
Anthrax - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2014 56
Anthrax - Pipeline by The Medicines Company, H2 2014 57
Anthrax - Pipeline by Vaxin, Inc., H2 2014 58
Assessment by Monotherapy Products, H2 2014 59
Assessment by Combination Products, H2 2014 60
Number of Products by Stage and Target, H2 2014 62
Number of Products by Stage and Mechanism of Action, H2 2014 64
Number of Products by Stage and Route of Administration, H2 2014 66
Number of Products by Stage and Molecule Type, H2 2014 68
Anthrax Therapeutics - Recent Pipeline Updates, H2 2014 131
Anthrax - Dormant Projects, H2 2014 145
Anthrax - Discontinued Products, H2 2014 146

[List of Figures]
Number of Products under Development for Anthrax, H2 2014 13
Number of Products under Development for Anthrax - Comparative Analysis, H2 2014 14
Number of Products under Development by Companies, H2 2014 15
Number of Products under Investigation by Universities/Institutes, H2 2014 18
Comparative Analysis by Late Stage Development, H2 2014 19
Comparative Analysis by Clinical Stage Development, H2 2014 20
Comparative Analysis by Early Stage Products, H2 2014 21
Assessment by Monotherapy Products, H2 2014 59
Number of Products by Top 10 Targets, H2 2014 61
Number of Products by Stage and Top 10 Targets, H2 2014 62
Number of Products by Top 10 Mechanism of Actions, H2 2014 63
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 64
Number of Products by Top 10 Routes of Administration, H2 2014 65
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 66
Number of Products by Top 10 Molecule Types, H2 2014 67
Number of Products by Stage and Top 10 Molecule Types, H2 2014 68

【掲載企業】

Aradigm Corporation
Bavarian Nordic A/S
Bristol-Myers Squibb Company
Cellceutix Corporation
ContraFect Corporation
Dynavax Technologies Corporation
Elusys Therapeutics, Inc.
Emergent BioSolutions Inc.
Evolva SA
Green Cross Corporation
Grifols, S.A.
Hawaii Biotech, Inc.
iBio, Inc.
Immunovaccine, Inc.
Innovative Biologics, Inc.
Microbiotix, Inc.
NanoBio Corporation
Navigen Pharmaceuticals, Inc.
Oragenics, Inc.
PaxVax
Pfenex Inc.
Planet Biotechnology Inc.
Protein Potential, LLC
ProThera Biologics, LLC.
PsiOxus Therapeutics, Ltd.
Revivicor, Inc.
SelectX Pharmaceuticals, Inc.
Soligenix, Inc.
Summit Corporation plc
Syntiron LLC
Tetraphase Pharmaceuticals Inc.
The Medicines Company
Vaxin, Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[炭疽(Anthrax):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆